Scholarlink

Purpose <p>This systematic review aimed to summarize the evidence on the association between multimorbidity and fluid biomarkers of Alzheimer’s disease (AD).</p> Methods <p>We systematically searched PubMed, Web of Science, and Embase for studies investigating the association between multimorbidity—defined as the co-occurrence of multiple chronic conditions in the same individual—and levels of cerebrospinal fluid (CSF) or blood biomarkers of AD, focusing on the most established AD biomarkers (amyloid-beta, phosphorylated-tau, total-tau, neurofilament light chain, and glial fibrillary acidic protein). Studies were selected following PRISMA guidelines. </p> Results <p>Out of 3,104 records, we identified 10 cross-sectional studies. Four studies assessed CSF biomarkers in dementia-free participants with mean age between 61.8 and 66.6&#xa0;years, yielding mixed findings with no consistent association between multimorbidity and CSF biomarkers. Six studies focused on blood biomarkers in participants with mean age ranging from 66.5 to 76.4&#xa0;years, five of which included individuals with dementia. Most of these studies reported an association between multimorbidity and elevated blood biomarker levels. </p> Conclusions <p>This review suggests a significant association between multimorbidity and AD blood biomarkers in older populations, while the results on CSF are mixed and inconsistent. Further research is needed, particularly longitudinal studies assessing both CSF and blood biomarkers within the same populations. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月20日

查看全文
  • Martina Valletta,
  • Marco Canevelli,
  • Francesca Gasparini,
  • Simona Buscarnera,
  • Martina Salzillo,
  • Federico Triolo,
  • Amaia Calderón-Larrañaga,
  • Alessandra Marengoni,
  • Davide Liborio Vetrano,
  • Giulia Grande

摘要

Purpose

This systematic review aimed to summarize the evidence on the association between multimorbidity and fluid biomarkers of Alzheimer’s disease (AD).

Methods

We systematically searched PubMed, Web of Science, and Embase for studies investigating the association between multimorbidity—defined as the co-occurrence of multiple chronic conditions in the same individual—and levels of cerebrospinal fluid (CSF) or blood biomarkers of AD, focusing on the most established AD biomarkers (amyloid-beta, phosphorylated-tau, total-tau, neurofilament light chain, and glial fibrillary acidic protein). Studies were selected following PRISMA guidelines.

Results

Out of 3,104 records, we identified 10 cross-sectional studies. Four studies assessed CSF biomarkers in dementia-free participants with mean age between 61.8 and 66.6 years, yielding mixed findings with no consistent association between multimorbidity and CSF biomarkers. Six studies focused on blood biomarkers in participants with mean age ranging from 66.5 to 76.4 years, five of which included individuals with dementia. Most of these studies reported an association between multimorbidity and elevated blood biomarker levels.

Conclusions

This review suggests a significant association between multimorbidity and AD blood biomarkers in older populations, while the results on CSF are mixed and inconsistent. Further research is needed, particularly longitudinal studies assessing both CSF and blood biomarkers within the same populations.